Despite advancements in the molecular biology of pancreatic cancer and discovery of key molecular lesions playing a part in the pathogenesis such as K-ras, p53, p16, and DPC4 (Deleted in Pancreatic Cancer 4 or Smad4), this progress has not been translated in therapeutic results. Here, KRAS is linked to familial pancreatic carcinoma.